Detalhe da pesquisa
1.
IDH-mutant myeloid neoplasms are associated with seronegative rheumatoid arthritis and innate immune activation.
Blood
; 143(18): 1873-1877, 2024 May 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-38457663
2.
Lineage-specific detection of residual disease predicts relapse in patients with chronic myeloid leukemia stopping therapy.
Blood
; 142(25): 2192-2197, 2023 12 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-37616555
3.
Genomic profiling for clinical decision making in myeloid neoplasms and acute leukemia.
Blood
; 140(21): 2228-2247, 2022 11 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-36130297
4.
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data.
Blood
; 140(11): 1200-1228, 2022 09 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-35767897
5.
Beyond BCR::ABL1-The Role of Genomic Analyses in the Management of CML.
J Natl Compr Canc Netw
; 22(1)2024 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-38394774
6.
Immune modulation in chronic myeloid leukaemia patients treated with nilotinib and interferon-alpha.
Br J Haematol
; 202(6): 1127-1136, 2023 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37482935
7.
Early BCR-ABL1 kinetics are predictive of subsequent achievement of treatment-free remission in chronic myeloid leukemia.
Blood
; 137(9): 1196-1207, 2021 03 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-32871588
8.
Molecular response in newly diagnosed chronic-phase chronic myeloid leukemia: prediction modeling and pathway analysis.
Haematologica
; 108(6): 1567-1578, 2023 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36727397
9.
Impact of additional genetic abnormalities at diagnosis of chronic myeloid leukemia for first-line imatinib-treated patients receiving proactive treatment intervention.
Haematologica
; 108(9): 2380-2395, 2023 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36951160
10.
The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1.
Nature
; 543(7647): 733-737, 2017 03 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-28329763
11.
Multiplex technologies for the assessment of minimal residual disease and low-level mutation detection in leukaemia: mass spectrometry versus next-generation sequencing.
Br J Haematol
; 196(1): 19-30, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34124782
12.
Measurable residual disease in chronic myeloid leukemia.
Haematologica
; 107(12): 2794-2809, 2022 12 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36453517
13.
Integrating genetic and epigenetic factors in chronic myeloid leukemia risk assessment: toward gene expression-based biomarkers.
Haematologica
; 107(2): 358-370, 2022 02 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34615339
14.
Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia.
N Engl J Med
; 376(10): 917-927, 2017 03 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-28273028
15.
Integrative genomic analysis reveals cancer-associated mutations at diagnosis of CML in patients with high-risk disease.
Blood
; 132(9): 948-961, 2018 08 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-29967129
16.
Why is it critical to achieve a deep molecular response in chronic myeloid leukemia?
Haematologica
; 105(12): 2730-2737, 2020 12 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33054104
17.
CRISPR-Cas9-mediated saturated mutagenesis screen predicts clinical drug resistance with improved accuracy.
Proc Natl Acad Sci U S A
; 114(44): 11751-11756, 2017 10 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-29078326
18.
De novo UBE2A mutations are recurrently acquired during chronic myeloid leukemia progression and interfere with myeloid differentiation pathways.
Haematologica
; 104(9): 1789-1797, 2019 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-30819912
19.
BCR::ABL1 digital PCR for treatment-free remission prediction in chronic myeloid leukemia patients: An individual participant data meta-analysis.
Am J Hematol
; 2024 May 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-38769689
20.
Taming the gatekeeper: ponatinib dose holds the key.
Blood
; 138(21): 2011-2012, 2021 11 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-34821935